Developing new antiviral drugs to treat COVID-19
Targeting SARS-CoV-2 PLpro for COVID-19 treatment
This study is working on developing new medicines that can help fight COVID-19 by targeting a specific part of the virus, aiming to improve treatment options for patients alongside vaccines.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-11009988 on NIH RePORTER |
What this research studies
This research focuses on creating new antiviral agents that target the papain-like protease (PLpro) of the SARS-CoV-2 virus, which is responsible for COVID-19. By using advanced techniques like structure-guided design and X-ray crystallography, the team is identifying novel binding sites for drug development. The goal is to optimize these inhibitors to effectively block viral replication and enhance treatment options for patients. This work aims to complement existing vaccines and provide additional tools to combat the pandemic.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with COVID-19 who may benefit from new antiviral therapies.
Not a fit: Patients who are not infected with SARS-CoV-2 or those who have mild cases that do not require antiviral treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective antiviral treatments that significantly reduce the severity and duration of COVID-19.
How similar studies have performed: Other research has shown promise in targeting viral proteases for antiviral drug development, indicating that this approach has potential for success.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Xiong, Rui — University of Arizona
- Study coordinator: Xiong, Rui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.